• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.

作者信息

Shipp M A, Abeloff M D, Antman K H, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford J A, Salles G, Schmitz N, Symann M, Armitage J O, Philip T, Coiffier B

机构信息

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

出版信息

J Clin Oncol. 1999 Jan;17(1):423-9. doi: 10.1200/JCO.1999.17.1.423.

DOI:10.1200/JCO.1999.17.1.423
PMID:10458261
Abstract
摘要

相似文献

1
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.侵袭性非霍奇金淋巴瘤大剂量造血干细胞移植治疗国际共识会议：评审团报告
J Clin Oncol. 1999 Jan;17(1):423-9. doi: 10.1200/JCO.1999.17.1.423.
2
International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.侵袭性非霍奇金淋巴瘤大剂量治疗联合造血干细胞移植国际共识会议：评审团报告
Ann Oncol. 1999 Jan;10(1):13-9. doi: 10.1023/a:1008397220178.
3
The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma.大剂量疗法联合造血干细胞救援在低度非霍奇金淋巴瘤中的作用。
Ann Oncol. 1993;4 Suppl 1:1-6. doi: 10.1093/annonc/4.suppl_1.s1.
4
High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?老年非霍奇金淋巴瘤患者的大剂量治疗及自体造血干细胞移植：可行，但适用于哪些患者？
J Geriatr Oncol. 2015 Sep;6(5):344-5. doi: 10.1016/j.jgo.2015.07.001. Epub 2015 Aug 10.
5
The management of adult aggressive non-Hodgkin's lymphomas.成人侵袭性非霍奇金淋巴瘤的管理
Crit Rev Oncol Hematol. 2000 Jul;35(1):33-48. doi: 10.1016/s1040-8428(99)00037-2.
6
Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation?哪些复发的非霍奇金淋巴瘤患者能从高剂量治疗和造血干细胞移植中获益？
J Clin Oncol. 1993 Oct;11(10):1841-3. doi: 10.1200/JCO.1993.11.10.1841.
7
[Salvage therapy in relapsed or refractory malignant lymphoma].[复发或难治性恶性淋巴瘤的挽救治疗]
Nihon Rinsho. 2000 Mar;58(3):699-703.
8
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.使用未预激和粒细胞集落刺激因子动员的外周血干细胞，对霍奇金病和非霍奇金淋巴瘤患者进行大剂量治疗后自体外周血干细胞移植。
J Clin Oncol. 1994 Oct;12(10):2176-86. doi: 10.1200/JCO.1994.12.10.2176.
9
[High dose therapy and hematopoietic stem cell transplantation in non-Hodgkin's lymphomas].[非霍奇金淋巴瘤的大剂量治疗与造血干细胞移植]
Pol Arch Med Wewn. 2001;105 Suppl:159-61.
10
The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.抗CD20抗体利妥昔单抗在非霍奇金淋巴瘤造血干细胞移植中的作用。
Curr Hematol Rep. 2005 Jul;4(4):276-83.

引用本文的文献

1
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.大剂量 90Y-替伊莫单抗（ibritumomab tiuxetan）预处理异基因移植对侵袭性大 B 细胞淋巴瘤有效。
Blood Adv. 2022 Jan 11;6(1):37-45. doi: 10.1182/bloodadvances.2021005056.
2
Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee.造血细胞移植和细胞治疗的系统评价：美国移植和细胞治疗学会、欧洲血液和骨髓移植学会以及国际血液和骨髓移植研究中心晚期效应和生活质量工作组的考虑因素和指导意见。
Transplant Cell Ther. 2021 May;27(5):380-388. doi: 10.1016/j.jtct.2020.12.002. Epub 2021 Jan 28.
3
Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee.造血细胞移植和细胞治疗的系统评价：美国移植和细胞治疗学会、欧洲血液和骨髓移植学会以及国际血液和骨髓移植研究中心晚期效应和生活质量工作组的考虑因素和指导意见。
Bone Marrow Transplant. 2021 Apr;56(4):786-797. doi: 10.1038/s41409-020-01199-1. Epub 2021 Jan 29.
4
Survival analysis of multiple myeloma patients after autologous stem cell transplantation.自体干细胞移植后多发性骨髓瘤患者的生存分析
Stem Cell Investig. 2019 Dec 12;6:42. doi: 10.21037/sci.2019.10.05. eCollection 2019.
5
Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma.用于评估复发/难治性弥漫性大B细胞淋巴瘤患者总体缓解率结局的Meta分析方法。
Oncotarget. 2019 May 14;10(35):3285-3293. doi: 10.18632/oncotarget.26904.
6
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.意大利关于 brentuximab vedotin 的真实世界经验：40 例复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究结果。
Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.
7
Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.接受维布妥昔单抗治疗后的长期缓解者：复发难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤患者的单中心经验
Oncologist. 2016 Dec;21(12):1436-1441. doi: 10.1634/theoncologist.2016-0112. Epub 2016 Aug 2.
8
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.稳健性：来那度胺-R-CHOP方案与安慰剂-R-CHOP方案治疗既往未治疗的ABC型弥漫性大B细胞淋巴瘤的对比
Future Oncol. 2016 Jul;12(13):1553-63. doi: 10.2217/fon-2016-0130. Epub 2016 Apr 18.
9
Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission.大剂量化疗后自体造血干细胞移植用于首次完全缓解的高危弥漫性大B细胞淋巴瘤的无事件生存情况良好。
Hematol Rep. 2015 Jun 8;7(2):5812. doi: 10.4081/hr.2015.5812. eCollection 2015 Jun 3.
10
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.在复发或难治性 CD30 阳性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤的日本患者中进行 brentuximab vedotin 的 I/II 期研究。
Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.